The University of Southampton
University of Southampton Institutional Repository

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma
The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma
Background: Patients with severe persistent asthma who are inadequately controlled despite treatment according to current asthma management guidelines have a significant unmet medical need. Such patients are at high risk of serious exacerbations and asthma-related mortality.
Methods: Here, we pooled data from seven studies to determine the effect of omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody, on asthma exacerbations in patients with severe persistent asthma. Omalizumab was added to current asthma therapy and compared with placebo (in five double-blind studies) or with current asthma therapy alone (in two open-label studies). The studies included 4308 patients (2511 treated with omalizumab), 93% of whom had severe persistent asthma according to the Global Initiative for Asthma (GINA) 2002 classification. Using the Poisson regression model, results were calculated as the ratio of treatment effect (omalizumab : control) on the standardized exacerbation rate per year.
Results: Omalizumab significantly reduced the rate of asthma exacerbations by 38% (P < 0.0001 vs control) and the rate of total emergency visits by 47% (P < 0.0001 vs control). Analysis of demographic subgroups showed that the efficacy of omalizumab on asthma exacerbations was unaffected by patient age, gender, baseline serum IgE (split by median) or by 2- or 4-weekly dosing schedule, although benefit in absolute terms appeared to be greatest in patients with more severe asthma, defined by a lower value of percentage predicted forced expiratory volume in 1 s (FEV?) at baseline.
Conclusions: These results suggest that omalizumab may fulfil an important need in patients with severe persistent asthma, many of whom are not adequately controlled on current therapy.
0105-4538
302-308
Bousquet, J.
fda25127-be6f-45cd-a455-883cc90d8e0e
Cabrera, P.
8cea10c2-316a-450c-adce-c984b5395d15
Berkman, N.
1553560f-11d1-4609-88d5-6d905cc66655
Buhl, R.
b18cd2c8-83e5-4c47-9220-aad364b2364e
Holgate, S.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Wenzel, S.
08a5766a-f896-44ac-9a0f-880fda76f9c1
Fox, H.
c1d9bcd3-e94b-414c-8a8f-5346064dc626
Hedgecock, S.
7a19fbf2-205c-4a28-bd88-c7caf1eb932a
Blogg, M.
924058ee-68fb-4090-b56b-ae356d7d0440
Cioppa, G. Della
6d6ccdc3-c19a-4f61-a15d-6c9921261abf
Bousquet, J.
fda25127-be6f-45cd-a455-883cc90d8e0e
Cabrera, P.
8cea10c2-316a-450c-adce-c984b5395d15
Berkman, N.
1553560f-11d1-4609-88d5-6d905cc66655
Buhl, R.
b18cd2c8-83e5-4c47-9220-aad364b2364e
Holgate, S.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Wenzel, S.
08a5766a-f896-44ac-9a0f-880fda76f9c1
Fox, H.
c1d9bcd3-e94b-414c-8a8f-5346064dc626
Hedgecock, S.
7a19fbf2-205c-4a28-bd88-c7caf1eb932a
Blogg, M.
924058ee-68fb-4090-b56b-ae356d7d0440
Cioppa, G. Della
6d6ccdc3-c19a-4f61-a15d-6c9921261abf

Bousquet, J., Cabrera, P., Berkman, N., Buhl, R., Holgate, S., Wenzel, S., Fox, H., Hedgecock, S., Blogg, M. and Cioppa, G. Della (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy, 60 (3), 302-308. (doi:10.1111/j.1398-9995.2004.00770.x).

Record type: Article

Abstract

Background: Patients with severe persistent asthma who are inadequately controlled despite treatment according to current asthma management guidelines have a significant unmet medical need. Such patients are at high risk of serious exacerbations and asthma-related mortality.
Methods: Here, we pooled data from seven studies to determine the effect of omalizumab, an anti-immunoglobulin E (IgE) monoclonal antibody, on asthma exacerbations in patients with severe persistent asthma. Omalizumab was added to current asthma therapy and compared with placebo (in five double-blind studies) or with current asthma therapy alone (in two open-label studies). The studies included 4308 patients (2511 treated with omalizumab), 93% of whom had severe persistent asthma according to the Global Initiative for Asthma (GINA) 2002 classification. Using the Poisson regression model, results were calculated as the ratio of treatment effect (omalizumab : control) on the standardized exacerbation rate per year.
Results: Omalizumab significantly reduced the rate of asthma exacerbations by 38% (P < 0.0001 vs control) and the rate of total emergency visits by 47% (P < 0.0001 vs control). Analysis of demographic subgroups showed that the efficacy of omalizumab on asthma exacerbations was unaffected by patient age, gender, baseline serum IgE (split by median) or by 2- or 4-weekly dosing schedule, although benefit in absolute terms appeared to be greatest in patients with more severe asthma, defined by a lower value of percentage predicted forced expiratory volume in 1 s (FEV?) at baseline.
Conclusions: These results suggest that omalizumab may fulfil an important need in patients with severe persistent asthma, many of whom are not adequately controlled on current therapy.

Full text not available from this repository.

More information

Published date: 2005

Identifiers

Local EPrints ID: 26951
URI: https://eprints.soton.ac.uk/id/eprint/26951
ISSN: 0105-4538
PURE UUID: aeae7ed2-9429-49bb-8f66-48c47ad41620

Catalogue record

Date deposited: 25 Apr 2006
Last modified: 17 Jul 2017 16:05

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×